Naval Daver, MD, Joseph D. Khoury, MD, FCAP - The Precision Team in AML: Exploring Pathologist-Informed Clinical Decisions in Challenging AML Settings

Go online to PeerView.com/XSA860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Are you ready to leverage the benefits of the wide range of
newly approved therapeutics that are revolutionizing patient care
in AML? Find out in this “Clinical Consults” activity based on a
recording at the 2023 USCAP Annual Meeting. A pathologist and a
hematologist-oncologist team up to discuss how modern diagnostic
techniques can lead to better, more collaborative, personalized
care using novel therapeutics to manage challenging AML cases
(including in high-risk and mutation-defined AML) and use cases to
illustrate diagnostic testing techniques and how pathology and
hem-onc can collaborate on treatment decision-making. Watch this
video activity today and hear how pathologists and
hematologist-oncologists can team up for better outcomes! Upon
completion of this activity, participants should be better able to:
Discuss the cytogenetic and histopathologic features that enable
diagnosis and influence prognosis of different AML subtypes,
including secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated
disease; Select appropriate molecular/pathology tests to establish
a diagnosis of AML or a specific AML subtype and collect relevant
information for subsequent treatment decisions; Summarize current
evidence supporting innovative cytotoxic, targeted, and
immunotherapy strategies in different AML subtypes, including
high-risk and mutation-defined disease; and Facilitate the
integration of novel therapeutics into team treatment plans
informed by baseline test results, including for patients with
secondary AML/AML-MRC or FLT3, IDH1/2, or TP53-mutated AML.